This page contents links to external websites. Please note that the accuracy, completeness and reliability of information contained in these websites is not the responsibility of LEO Pharma UK/IE and the use of these links does not imply any recommendation or endorsement by LEO Pharma UK/IE.
LEO Pharma recognises the important role of working closely with patient advocacy groups to raise awareness of the varied and often significant challenges people face living with dermatological conditions and call for positive change. We are therefore extremely proud to have partnered with the National Eczema Society to commission the ‘Eczema Unmasked’ report, with insights from over 1,000 people affected by the condition.
Eczema Unmasked raises awareness of the extensive and under-recognised impact eczema can have on all aspects of peoples’ lives including impact on people’s physical health, mental health, their quality of life, long-term life opportunities – highlighting the variation in healthcare provision and measures that must be taken to bridge these gaps in care.
Based on these findings LEO Pharma and the National Eczema Society are calling for the voices of those living with eczema to be strengthened, the development of clinical guidelines and quality standards for adults and adolescents with eczema and lastly, improve access to appropriate care and services.
Eczema can affect physical health: 96% of adults and 95% of children experienced itchy skin, many severely, and 67% of adults and 60% of children have had skin so sore that it bleeds.
Eczema can affect mental health: Almost three quarters of adults (74%) stating it had negatively impacted their mental health and 2/3 (66%) of patients said they were lonely/socially isolated because of their eczema. Despite this, less than half had been offered access to emotional or psychological support to help them to manage this.
Eczema can affect day to day life: 89% of adults said eczema significantly reduced their quality of life and 76% of parents said their child’s quality of life is significantly affected.
Eczema can limit life opportunities: Nearly half of adult responders (49%) said eczema had affected their ability to do paid work.
Accessing care and treatment can be challenging: Nearly a third (29%) of adults, and a third (33%) of parents say they have difficulty obtaining the emollients they need from the NHS, while over a quarter (28%) say the same about challenges accessing biologic treatment.
LEO Pharma and the National Eczema Society’s ‘Eczema Unmasked’ report aims to better represent the experiences of adults with eczema and serve as a new, robust evidence base to demonstrate how eczema can significantly impact people’s physical health, mental health, their quality of life, long-term life opportunities and access to appropriate care.
“There are no national clinical guidelines and quality standards to guide diagnosis and management of eczema in adolescents or adults, leading to huge variations of care. Greater standardisation in clinical care driven by evidence-based treatment guidelines is desperately needed to improve patient outcomes, guide commissioning decisions and prioritise healthcare resources effectively.”
– Funmi Oluwa, Market Access & External Affairs Director, LEO Pharma UK/IE.
“It’s important to better understand the full impact of living with eczema and for patients to get the treatment and support they need to manage this painful medical condition. These survey responses show just how tough it can be living with eczema.”
– Andrew Proctor, Chief Executive, National Eczema Society
The Eczema Unmasked report is a collaboration between the National Eczema Society and LEO Pharma. LEO Pharma has provided core funding, editorial input and undertaken survey-based research to support the development of the report. The content was approved by National Eczema Society and reviewed by LEO Pharma to ensure compliance with the ABPI Code of Practice.